OrbiMed Advisors
http://www.orbimed.com/OrbiMed is the world's largest healthcare-dedicated investment firm, with approximately $5 billion in assets under management. The firm was stated in 1989 with a vision to invest across the spectrum of healthcare companies: from private start-ups to large multinational companies.
View Older Stories View More Recent Stories
-
Form SC 13D/A Prelude Therapeutics Filed by: ORBIMED ADVISORS LLC
-
Terns Completes Enrollment in Phase 2a Clinical Trial of TERN-101 in NASH Patients
-
Form 4 CTI BIOPHARMA CORP For: Jan 07 Filed by: ORBIMED ADVISORS LLC
-
Vivo Capital Appoints New Managing Partners and Partners
-
Form 3 Verona Pharma plc For: Jan 01 Filed by: ORBIMED ADVISORS LLC
-
Terns Appoints Three New Independent Directors to its Board
-
Pharvaris Expands Board of Directors with Appointment of David Meeker, M.D., as Chair and Robert Glassman, M.D., as Director
-
Terns Closes $87 Million Series C Financing to Advance NASH Portfolio
-
Form 4 ALPINE IMMUNE SCIENCES, For: Dec 28 Filed by: ORBIMED ADVISORS LLC
-
Form SC 13D/A ALPINE IMMUNE SCIENCES, Filed by: ORBIMED ADVISORS LLC
-
ClearPoint Neuro, Inc. Announces Funding of Additional $7.5M of Existing Convertible Note on Improved Terms
-
Form SC 13D Silverback Therapeutics, Filed by: ORBIMED ADVISORS LLC
-
Form SC 13D Kinnate Biopharma Inc. Filed by: ORBIMED ADVISORS LLC
-
Form 4 Silverback Therapeutics, For: Dec 08 Filed by: ORBIMED ADVISORS LLC
-
Syros Closes $90.5 Million Strategic Financing
-
Sinovac Reports Unaudited Third Quarter 2020 Financial Results
-
Thiel-backed therapy developer AbCellera looks to raise up to $391 million in IPO
-
Form 3 Kinnate Biopharma Inc. For: Dec 02 Filed by: ORBIMED ADVISORS LLC
-
Genenta to Appoint Stephen Squinto, Experienced Biotech Executive and Investor, as Chairman
-
Form SC 13D/A Keros Therapeutics, Inc. Filed by: ORBIMED ADVISORS LLC
-
Ikena Oncology Assembles Multi-Disciplinary Scientific Advisory Board
-
Form SC 13D/A Oric Pharmaceuticals, Filed by: ORBIMED ADVISORS LLC
-
Form 13F-HR ORBIMED ADVISORS LLC For: Sep 30
-
PMV Pharmaceuticals Reports Third Quarter 2020 Financial Results and Corporate Highlights
-
PMV Pharmaceuticals Reports Third Quarter 2020 Financial Results and Corporate Highlights
-
Form SC 13D/A Aerpio Pharmaceuticals, Filed by: ORBIMED ADVISORS LLC
-
Edgewise Therapeutics Initiates Phase 1 Clinical Trial of EDG-5506 in Becker Muscular Dystrophy
-
Ikena Oncology to Present New Preclinical Data on AHR Antagonist IK-175 at the Society for Immunotherapy of Cancer’s 2020 Annual Meeting
-
Form SC 13D Galecto, Inc. Filed by: ORBIMED ADVISORS LLC
-
Natera Reports Third Quarter 2020 Financial Results
-
Form 4 Galecto, Inc. For: Nov 02 Filed by: ORBIMED ADVISORS LLC
-
Petrichor Closes Oversubscribed Fund I at $410 Million
-
Edgewise Therapeutics Appoints John Moore as General Counsel
-
Q32 Bio Closes $60 Million Series B Financing, Advances to Clinical Stage Research in Therapeutics Designed to Restore Immune Homeostasis
-
Form 3 Galecto Inc. For: Oct 28 Filed by: ORBIMED ADVISORS LLC
-
Steven Yecies Joins Javelin Oncology as Chief Executive Officer
-
5 Biotech Penny Stocks To Watch With Recent & Upcoming Events
-
Form SC 13D/A BELLUS Health Inc. Filed by: ORBIMED ADVISORS LLC
-
Edgewise Therapeutics Appoints Behrad Derakhshan as Chief Business Officer
-
Inspire Medical Systems, Inc. Announces Appointment of Seasoned Senior Corporate Executive Shelley Broader to its Board of Directors
-
Edgewise Therapeutics Appoints Michael Carruthers as Chief Financial Officer
-
Form SC 13D/A SpringWorks Therapeutics Filed by: ORBIMED ADVISORS LLC
-
Form SC 13D/A Arcutis Biotherapeutics, Filed by: ORBIMED ADVISORS LLC
-
Form SC 13D/A LogicBio Therapeutics, Filed by: ORBIMED ADVISORS LLC
-
Arcutis Biotherapeutics Announces Closing of Public Offering and Concurrent Private Placement of Common Stock
-
Form SC 13D GRAYBUG VISION, INC. Filed by: ORBIMED ADVISORS LLC
-
Form SC 13D/A Xtant Medical Holdings, Filed by: ORBIMED ADVISORS LLC
-
Form SC 13D PMV Pharmaceuticals, Filed by: ORBIMED ADVISORS LLC
-
Form SC 13D Prelude Therapeutics Filed by: ORBIMED ADVISORS LLC
-
Form 4 Xtant Medical Holdings, For: Oct 01 Filed by: ORBIMED ADVISORS LLC

